Genmab: all 77 studies

Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian CancerNot yet recruitingNCT07859215Phase 3
• Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingNCT07775287Phase 3
• Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)RecruitingNCT07702032Phase 3
• A Phase 1 Trial of GEN1119 in Participants With Solid TumorsRecruitingNCT07695831Phase 1
• An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingNCT07604766Phase 3
• Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingNCT07564141Phase 3
• Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) CancersRecruitingNCT07539311Phase 2
• A Study of GEN1106 in Participants With Solid TumorsRecruitingNCT07416123Phase 1
• Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid TumorsRecruitingNCT07387068Phase 1
• First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)RecruitingNCT07384715Phase 1
• Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerRecruitingNCT07288177Phase 2
• Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet ChemotherapyRecruitingNCT07225270Phase 3
• Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerRecruitingNCT07166094Phase 3
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/2
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingNCT03526835Phase 1/2
• Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedNCT06984328Phase 2Results posted
• Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination TherapyTerminatedNCT06391775Phase 1/2Results posted
• A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin LymphomaTerminatedNCT06018129Phase 1/2Results posted
• A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsTerminatedNCT05491317Phase 1/2Results posted
• A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as MonotherapyTerminatedNCT05435339Phase 1/2Results posted
• GEN3014 Trial in Relapsed or Refractory Hematologic MalignanciesTerminatedNCT04824794Phase 1/2Results posted
• A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid TumorsTerminatedNCT04424641Phase 1/2Results posted
• First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin LymphomasTerminatedNCT04358458Phase 1/2Results posted
• GEN1046 Safety Trial in Patients With Malignant Solid TumorsTerminatedNCT03917381Phase 1/2Results posted
• GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid TumorsTerminatedNCT03576131Phase 1/2Results posted
• MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.CompletedNCT03321981Phase 2Results posted
• Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02988817Phase 1/2Results posted
• Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)CompletedNCT01054625Phase 1/2Results posted
• Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based ChemotherapyTerminatedNCT00707655Phase 1/2Results posted
• Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal CancerTerminatedNCT00677924Phase 1/2Results posted
• Zalutumumab in Non-curable Patients With SCCHNCompletedNCT00542308Phase 2Results posted
• Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung CancerTerminatedNCT00460551Phase 2Results posted
• Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck CancerTerminatedNCT00401401Phase 1/2Results posted
• Zalutumumab in Patients With Non-curable Head and Neck CancerCompletedNCT00382031Phase 3Results posted
• Zalutumumab in Head and Neck CancerCompletedNCT00093041Phase 1/2Results posted
• Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerWithdrawnNCT07353957Phase 2
• A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaActive, not recruitingNCT07226752Phase 3
• A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid TumorsTerminatedNCT06771921Phase 1/2
• A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid TumorsTerminatedNCT06685068Phase 1/2
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Active, not recruitingNCT06635824Phase 3
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerActive, not recruitingNCT06619236Phase 3
• Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid TumorsTerminatedNCT06573294Phase 1
• A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Active, not recruitingNCT06525220Phase 3
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06508658Phase 3
• A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)Active, not recruitingNCT06496178Phase 3
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaActive, not recruitingNCT06191744Phase 3
• PRO1107 in Patients With Advanced Solid TumorsTerminatedNCT06171789Phase 1/2
• A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsActive, not recruitingNCT06057038Phase 1
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerWithdrawnNCT06046274Phase 2
• Expanded Access Program for EpcoritamabApproved for marketingNCT05733650
• Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)TerminatedNCT05721222Phase 1/2
• Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaTerminatedNCT05660967Phase 2
• Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid TumorsCompletedNCT05586321Phase 1
• A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT05578976Phase 3
• A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaActive, not recruitingNCT05451810Phase 2
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular LymphomaActive, not recruitingNCT05409066Phase 3
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingNCT05283720Phase 2
• Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of EpcoritamabActive, not recruitingNCT05206357Phase 1
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05201248Phase 1/2
• GEN1047 for Solid Tumors - First in Human (FIH) TrialTerminatedNCT05180474Phase 1/2
• Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerTerminatedNCT05117242Phase 2
• GEN1046 Safety and PK in Subjects With Advanced Solid MalignanciesCompletedNCT04937153Phase 1
• Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationActive, not recruitingNCT04868877Phase 1/2
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruitingNCT04663347Phase 1/2
• A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04628494Phase 3
• Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeActive, not recruitingNCT04623541Phase 1/2
• Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)Active, not recruitingNCT04542824Phase 1/2
• Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorApproved for marketingNCT04100694
• GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsActive, not recruitingNCT04083599Phase 1/2
• A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic MalignanciesCompletedNCT03922204Phase 1
• A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid MalignanciesCompletedNCT03913741Phase 1/2
• First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaActive, not recruitingNCT03625037Phase 1/2
• MCLA-117 in Acute Myelogenous LeukemiaTerminatedNCT03038230Phase 1
• Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase InhibitorsWithdrawnNCT01449357Phase 2
• Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.CompletedNCT00071084Phase 2
• Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.CompletedNCT00071071Phase 2
• Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha BlockerTerminatedNCT00042406Phase 2/3

← Genmab overview and focus areas